Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
about
Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Triple-negative breast cancer: role of specific chemotherapy agentsIntensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.Management options in triple-negative breast cancerBasal breast cancer: a complex and deadly molecular subtypeLow-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study.Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-ActivationMobilization of Peripheral Blood Stem Cells Using Regimen Combining Docetaxel with Granulocyte Colony-stimulating Factor in Breast Cancer Patients.Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer RegistryThe effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.Pharmacotherapy of triple-negative breast cancer.Triple-negative breast cancer--current status and future directions.Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.Beyond triple-negative breast cancer: the need to define new subtypes.Triple-negative breast cancer: unique biology and its management.Triple-negative breast cancer: making the most of a misnomer.Dose-dense chemotherapy for breast cancer.Adjuvant treatments for triple-negative breast cancers.High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer.BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial
P2860
Q27853207-69AEEBF6-D6B4-4696-B615-1BCFBC2480F4Q33710233-5D13D7FC-080C-49C0-9A79-698C97040248Q33769821-7AA175B4-7F5F-4DA4-9065-9FA700BD4813Q33900930-52BE84AC-6880-4467-9962-2F36031F4706Q34886445-AA2641E6-4CAE-47E4-A55D-2107A054AF18Q35145663-5520C6F9-4DAF-4770-BF43-5B22576BBEC3Q35155460-FACF9D73-3221-4ECB-8DD8-6C1FE20FD457Q35931900-F98826A8-9A73-4ACD-AF33-40891AE69A5AQ36057458-290B13CD-7F4F-4B4E-8E7A-9E047FB00DAFQ36528656-5E966BE1-C03E-4F4B-AFFF-1A5B586EEDA0Q36530636-19750921-7989-4646-AA6A-46657B56E1F9Q36630127-01949AD0-E670-494D-9970-508A6AB9C993Q36654613-EADB4171-3113-4111-A05A-69BFFBEAA4A1Q37205563-050689C7-4604-4738-820C-AE9C10151A0BQ37289219-826920D0-C282-404D-9BBF-CA83EDB2BE74Q37360151-47DAA272-9F89-4635-B476-BD726D78135EQ37385293-11C51DD1-B3DE-44B1-93CE-F45057BF55DFQ37477489-903F7F0D-F92D-4E92-84C4-5D7A62B0C739Q37565645-6EAB0E1C-CC74-4BD8-BA9C-CD9F2B7271E2Q37630082-65609C97-D1FA-4FC9-A4C1-580430144B95Q37650748-7FB277D2-4067-4D8B-9B92-44B9746DE2F4Q37687380-D3484742-BBB4-4F90-AFA3-A8AC507B7D70Q37782088-CAA05A0D-8C63-45D0-B84D-21511FA40C93Q37788688-B117DBEC-66C3-4FC6-8431-17FC2E47A245Q38004606-54A97808-EC80-481F-A098-ED510F6205B3Q38009885-C5CE0827-D6C3-48F6-B025-EEFB0FE187DDQ38046581-8C09D49C-89F4-4B0C-A0AB-FACEB6D172FCQ40847140-4C7BAE4E-FEDE-46C0-BD3A-6DF75E335458Q40870110-A71ECF04-BDD0-488B-8B17-E81DCA4BEF29Q42483948-8F9E4CF2-9B4B-4529-A068-4E237356F7A5Q47788774-9146B888-4B4E-4E4B-9BED-67901BDBCB1BQ54405768-C49224CC-706F-4112-9083-3770F7340651Q54965602-B2351FB7-1670-4643-B71C-DACEE7CE9C34Q55428234-BCB78D4D-B24F-42AE-A27A-E0D45A5A6ACAQ57904482-21D57E9E-2066-4B26-A59A-5C84840CC722
P2860
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Triple-negative high-risk brea ...... y: results of WSG AM-01 trial.
@en
Triple-negative high-risk brea ...... y: results of WSG AM-01 trial.
@nl
type
label
Triple-negative high-risk brea ...... y: results of WSG AM-01 trial.
@en
Triple-negative high-risk brea ...... y: results of WSG AM-01 trial.
@nl
prefLabel
Triple-negative high-risk brea ...... y: results of WSG AM-01 trial.
@en
Triple-negative high-risk brea ...... y: results of WSG AM-01 trial.
@nl
P2093
P2860
P356
P1433
P1476
Triple-negative high-risk brea ...... y: results of WSG AM-01 trial.
@en
P2093
C Jackisch
H Kirchner
P2860
P304
P356
10.1093/ANNONC/MDM551
P577
2008-01-03T00:00:00Z